Efficacy of COVID-19 vaccines : a systematic review and network meta-analysis of phase 3 randomized controlled trials
© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences..
Several vaccines have been approved for the prevention of COVID-19. However, no head-to-head trials comparing their clinical efficacy have been performed. This network meta-analysis aims to identify those, among the competing existing vaccines, conferring the maximum protection against COVID-19. A literature search was done in Medline (via PubMed), Embase and Cochrane Library databases for phase 3 randomized controlled trials evaluating the efficacy of different COVID-19 vaccines. Search results were screened and eligible studies were included to perform a network meta-analysis in software 'R' version 4.1.2 using a random effect model. Cochrane's 'Risk of Bias tool (RoB2)' was used for quality assessment. Raw data from the included studies was used for network meta-analysis. Assessment of inconsistency was not possible as no study compared two or more vaccines directly. A forest plot for indirect comparison of various COVID-19 vaccines was obtained. Rankogram and 'P' scores were obtained to rank the vaccines based on the indirect evidence of their comparative efficacy. A total of 17 randomized controlled trials evaluating the efficacy of 16 COVID-19 vaccines, were included in the network meta-analysis. A total of 361,386 participants was included in this network meta-analysis. Overall risk of bias among included studies was of 'some concern'. All the COVID-19 vaccines had a statistically significant reduction of risk for contracting symptomatic SARS-CoV-2 in comparison to the placebo, however, the maximum protection (RR 0.05) was with BNT126b2. The indirect comparison also revealed BNT126b2 vaccine confers the highest protection against symptomatic SARS-CoV-2 infection in comparison to all others included, with a 'P' score of 0.9771 followed by mRNA-1273, rAD26 & rAD5 and NVX-CoV2373. The evidence generated from this network meta-analysis indicates the good efficacy of all the included vaccines in preventing symptomatic COVID-19 as compared to placebo. The BNT126b2 vaccine was found to provide the highest protection against symptomatic SARS-CoV-2 among all included followed by mRNA-1273, rAD26 & rAD5, NVX-CoV2373 and others.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Pharmacological reports : PR - 74(2022), 6 vom: 07. Dez., Seite 1228-1237 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Subodh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 15.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43440-022-00429-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348565003 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348565003 | ||
| 003 | DE-627 | ||
| 005 | 20231226040542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-022-00429-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348565003 | ||
| 035 | |a (NLM)36342658 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Subodh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of COVID-19 vaccines |b a systematic review and network meta-analysis of phase 3 randomized controlled trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences. | ||
| 520 | |a Several vaccines have been approved for the prevention of COVID-19. However, no head-to-head trials comparing their clinical efficacy have been performed. This network meta-analysis aims to identify those, among the competing existing vaccines, conferring the maximum protection against COVID-19. A literature search was done in Medline (via PubMed), Embase and Cochrane Library databases for phase 3 randomized controlled trials evaluating the efficacy of different COVID-19 vaccines. Search results were screened and eligible studies were included to perform a network meta-analysis in software 'R' version 4.1.2 using a random effect model. Cochrane's 'Risk of Bias tool (RoB2)' was used for quality assessment. Raw data from the included studies was used for network meta-analysis. Assessment of inconsistency was not possible as no study compared two or more vaccines directly. A forest plot for indirect comparison of various COVID-19 vaccines was obtained. Rankogram and 'P' scores were obtained to rank the vaccines based on the indirect evidence of their comparative efficacy. A total of 17 randomized controlled trials evaluating the efficacy of 16 COVID-19 vaccines, were included in the network meta-analysis. A total of 361,386 participants was included in this network meta-analysis. Overall risk of bias among included studies was of 'some concern'. All the COVID-19 vaccines had a statistically significant reduction of risk for contracting symptomatic SARS-CoV-2 in comparison to the placebo, however, the maximum protection (RR 0.05) was with BNT126b2. The indirect comparison also revealed BNT126b2 vaccine confers the highest protection against symptomatic SARS-CoV-2 infection in comparison to all others included, with a 'P' score of 0.9771 followed by mRNA-1273, rAD26 & rAD5 and NVX-CoV2373. The evidence generated from this network meta-analysis indicates the good efficacy of all the included vaccines in preventing symptomatic COVID-19 as compared to placebo. The BNT126b2 vaccine was found to provide the highest protection against symptomatic SARS-CoV-2 among all included followed by mRNA-1273, rAD26 & rAD5, NVX-CoV2373 and others | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Network meta-analysis | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 700 | 1 | |a Saikia, Dibyajyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Bankar, Mangesh |e verfasserin |4 aut | |
| 700 | 1 | |a Saurabh, Manoj Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Harminder |e verfasserin |4 aut | |
| 700 | 1 | |a Varikasuvu, Sheshadri Reddy |e verfasserin |4 aut | |
| 700 | 1 | |a Maharshi, Vikas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports : PR |d 2005 |g 74(2022), 6 vom: 07. Dez., Seite 1228-1237 |w (DE-627)NLM154978965 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:6 |g day:07 |g month:12 |g pages:1228-1237 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43440-022-00429-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 6 |b 07 |c 12 |h 1228-1237 | ||